| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H28FNO3 |
| Molecular Weight | 373.461 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(=CC=C1)[C@H](O)C2CCN(CCC3=CC=C(F)C=C3)CC2
InChI
InChIKey=HXTGXYRHXAGCFP-OAQYLSRUSA-N
InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
| Molecular Formula | C22H28FNO3 |
| Molecular Weight | 373.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Volinanserin (MDL-100,907) is a highly selective 5-HT2A receptor antagonist. It is widely used in
scientific research to investigate the function of the 5-HT2A receptor. Volinanserin is also being trialed as a
potential antipsychotic, antidepressant and treatment for insomnia. Volinanserin (M-100907) was in
phase III trials for chronic schizophrenia. In August 1999, development was discontinued for acute
schizophrenia (schizoaffective disorder) on the basis of poor results. M-100907 is also active in animal
models involving blockade of NMDA glutamatergic channel receptors, an effect known to resemble some
behavioral symptoms of schizophrenia in man. M-100907 is also claimed in other patents for the
treatment of thromboembolic disorders, for the treatment of various developmental neurological
disorders such as autism and attention deficit hyperactivity disorder.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Schizophrenia treatment: an oral dose of 20 mg per day ensures adequate 5HT(2A) receptor occupancy for clinical proof of concept.
Route of Administration:
Oral
